Select Language
Free Registration

HLA-A*1101 & B2M & EBV (AVFDRKSDAK)

HLA-A*1101 & B2M & EBV (AVFDRKSDAK) Product List

  • Product Category

    Protein (2)

  • Product Status

    Launched (2)

  • Species

    Human (2)

  • Tag

    His Tag & Avi Tag (1)His Tag (1)

  • Conjugate

    Biotin-labeled (1)PE Labeled (1)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeature
HLE-H82E5
Human
HEK293
Biotinylated Human HLA-A*11:01&B2M&EBV (AVFDRKSDAK) Complex Protein (Monomer, MALS verified)
HLE-HP2H4
Human
HEK293
PE-Labeled Human HLA-A*11:01&B2M&EBV (AVFDRKSDAK) Tetramer Protein
Total: 2
  • 1

HLA-A*1101 & B2M & EBV (AVFDRKSDAK) Background

Epstein-Bar Virus (EBV), also known as human herpesvirus 4, belongs to gamma herpes virus family and is a very common human virus worldwide. EBV causes infectious mononucleosis (IM) and also associates to some specific types of cancers such as Burkitt’s lymphoma (BL) and gastric carcinoma (GC). Glycoprotein B (gB) plays an important role in viral entry by binding with αvβ6/αvβ8 integrins to trigger the membrane fusion and entry process of epithelial cells, which makes it become an great target for EBV research. Epstein-Bar Virus (EBV), also known as human herpesvirus 4, belongs to gamma herpes virus family and is a very common human virus worldwide. EBV causes infectious mononucleosis (IM) and also associates to some specific types of cancers such as Burkitt’s lymphoma (BL) and gastric carcinoma (GC). Glycoprotein B (gB) plays an important role in viral entry by binding with αvβ6/αvβ8 integrins to trigger the membrane fusion and entry process of epithelial cells, which makes it become an great target for EBV research. The Human HLA-A*1101 EBV (AVFDRKSDAK) complex protein is a complex of HLA-A*1101 of the MHC Class I, B2M and AVFDRKSDAK peptide of the EBV.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Alintegimod7HP349; 7-HP-349; 7HP-349Phase 2 Clinical7 Hills Pharma LLCKidney Neoplasms; Liver Neoplasms; Solid tumours; Mismatch Repair Deficient Cancer; Carcinoma, Renal Cell; Neoplasms; Skin Neoplasms; Mesothelioma; Colorectal Neoplasms; Melanoma; Neoplasm Metastasis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
LifitegrastSHP-606; SAR-1119; SAR-1118; OJL-332; SPD-606ApprovedShire Development LlcXiidraUnited StatesDry Eye SyndromesBausch And Lomb Inc2016-07-11Keratoconjunctivitis Sicca; Graft vs Host Disease; Dry Eye Syndromes; Diabetic macular oedema; Conjunctivitis, Allergic; Xerophthalmia
Details
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information
Share to:

Join UsLegalSite MapPrivacy PolicyTerms and Conditions
Website Feedback
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

order@acrobiosystems.com

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland